Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 7/2012

Open Access 01-07-2012 | Article

The usefulness of arbekacin compared to vancomycin

Authors: J.-H. Hwang, J.-H. Lee, M.-K. Moon, J.-S. Kim, K.-S. Won, C.-S. Lee

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 7/2012

Login to get access

Abstract

The bacteriological efficacy response (improved, arbekacin vs. vancomycin; 71.2% vs. 79.5%) and clinical efficacy response (improved, arbekacin vs. vancomycin; 65.3% vs. 76.1%) were not statistically different between the two groups. The complication rate was significantly higher in the vancomycin group (32.9%) compared to the arbekacin group (15.1%) (p = 0.019). Arbekacin was not inferior to vancomycin, and it could be a good alternative drug for vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) treatment.
Literature
1.
Ma XX, Ito T, Tiensasitorn C, Jamklang M, Chongtrakool P, Boyle-Vavra S, Daum RS, Hiramatsu K (2002) Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 46(4):1147–1152PubMedCrossRef
2.
Chung GT, Cha JG, Han SY, Jang HS, Lee KM, Yoo JI, Yoo JS, Kim HB, Eun SH, Kim BS, Park O, Lee YS (2010) Nationwide surveillance study of vancomycin intermediate Staphylococcus aureus strains in Korean Hospitals from 2001 to 2006. J Microbiol Biotechnol 20(3):637–642PubMed
3.
Lee KW, Lee MA, Lee CH, Lee JW, Roh KH, Kim SJ, Kim JJ, Koh EM, Yong DE, Chong YS, KONSAR Group (2010) Increase of ceftazidime- and fluoroquinolone-resistant Klebsiella pneumoniae and imipenem-resistant Acinetobacter spp. in Korea: analysis of KONSAR study data from 2005 and 2007. Yonsei Med J 51(6):901–911PubMedCrossRef
4.
Kim JM, Park ES, Jeong JS, Kim KM, Kim JM, Oh HS, Yoon SW, Chang HS, Chang KH, Lee SI, Lee MS, Song JH, Kang MW, Park SC, Choe KW, Pai CH (2000) Multicenter surveillance study for nosocomial infections in major hospitals in Korea. Nosocomial Infection Surveillance Committee of the Korean Society for Nosocomial Infection Control. Am J Infect Control 28(6):454–458PubMedCrossRef
5.
Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC (1997) Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40(1):135–136PubMedCrossRef
6.
Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, Tenover FC, Zervos MJ, Band JD, White E, Jarvis WR (1999) Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 340(7):493–501PubMedCrossRef
7.
Centers for Disease Control and Prevention (CDC) (2000) Staphylococcus aureus with reduced susceptibility to vancomycin—Illinois, 1999. MMWR Morb Mortal Wkly Rep 48(51–52):1165–1167
8.
Wie SH, Kang JH, Huh DH, Lee DG, Kim SI, Kim YR, Choi JH, Kim JH, Yoo JH, Hur JK, Shin WS, Kang MW (2001) Antimicrobial activities of arbekacin against clinical isolates of Staphylococcus aureus and coagulase-negative Staphylococcus species. Korean J Infect Dis 33(4):254–260
9.
Watanabe T, Ohashi K, Matsui K, Kubota T (1997) Comparative studies of the bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 39(4):471–476PubMedCrossRef
10.
Kim TH, Choo EJ, Lee MS, Kim NJ, Woo JH, Ryu J, Chang MS, Yum YK (2003) Clinical efficacy and safety with arbekacin for methicillin-resistant Staphylococcus aureus (MRSA) infections. Korean J Med 65(2):239–244
11.
Manjunath G, Sarnak MJ, Levey AS (2001) Prediction equations to estimate glomerular filtration rate: an update. Curr Opin Nephrol Hypertens 10(6):785–792PubMedCrossRef
12.
Mackowiak PA, LeMaistre CF (1987) Drug fever: a critical appraisal of conventional concepts. An analysis of 51 episodes in two Dallas hospitals and 97 episodes reported in the English literature. Ann Intern Med 106(5):728–733PubMed
13.
Choo EJ, Choi SH, Cho YW, Chung SM, Kim BN, Kim NJ et al (2002) Clinical experience with quinupristin–dalfopristin treatment for vancomycin-resistant enterococcal infection. J Korean Soc Chemother 20(1):17–24
14.
Rosenthal VD, Maki DG, Mehta A, Alvarez-Moreno C, Leblebicioglu H, Higuera F, Cuellar LE, Madani N, Mitrev Z, Dueñas L, Navoa-Ng JA, Garcell HG, Raka L, Hidalgo RF, Medeiros EA, Kanj SS, Abubakar S, Nercelles P, Pratesi RD, International Nosocomial Infection Control Consortium Members (2008) International Nosocomial Infection Control Consortium report, data summary for 2002–2007, issued January 2008. Am J Infect Control 36(9):627–637PubMedCrossRef
15.
Burton DC, Edwards JR, Horan TC, Jernigan JA, Fridkin SK (2009) Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997–2007. JAMA 301(7):727–736PubMedCrossRef
16.
Wang G, Hindler JF, Ward KW, Bruckner DA (2006) Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 44(11):3883–3886PubMedCrossRef
17.
Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC (2008) Vancomycin-resistant Staphylococcus aureus in the United States, 2002–2006. Clin Infect Dis 46(5):668–674PubMedCrossRef
18.
Sato R, Tanigawara Y, Kaku M, Aikawa N, Shimizu K (2006) Pharmacokinetic–pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 50(11):3763–3769PubMedCrossRef
19.
Lee DG, Chun HS, Yim DS, Choi SM, Choi JH, Yoo JH, Shin WS, Kang MW (2003) Efficacies of vancomycin, arbekacin, and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in an in vitro infective endocarditis model. Antimicrob Agents Chemother 47(12):3768–3773PubMedCrossRef
20.
Hamilton-Miller JM, Shah S (1995) Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 35(6):865–868PubMedCrossRef
21.
Suzuki K (2003) Efficacy and safety of arbekacin for staphylococcal infection in the NICU. Pediatr Int 45(3):301–306PubMedCrossRef
22.
23.
Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL (2009) Relationship between initial vancomycin concentration–time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 49(4):507–514PubMedCrossRef
Metadata
Title
The usefulness of arbekacin compared to vancomycin
Authors
J.-H. Hwang
J.-H. Lee
M.-K. Moon
J.-S. Kim
K.-S. Won
C.-S. Lee
Publication date
01-07-2012
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 7/2012
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-011-1490-9

Other articles of this Issue 7/2012

European Journal of Clinical Microbiology & Infectious Diseases 7/2012 Go to the issue

Article

Curcumin suppresses Streptococcus mutans adherence to human tooth surfaces and extracellular matrix proteins

Article

Evaluation of various cytokines elicited during antigen-specific recall as potential risk indicators for the differential development of leprosy

Article

In vivo evaluation of a metronidazole-containing gel for the adjuvant treatment of chronic periodontitis: preliminary results

Article

The altered expression of α1 and β3 subunits of the gamma-aminobutyric acid A receptor is related to the hepatitis C virus infection

Article

Performance of the GenoType® MTBDRPlus assay in routine settings: a multicenter study

Article

Subtype analysis of Blastocystis isolates in Swedish patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits